Fischer Medical Ventures Ltd Subsidiary Secures ₹40 Crore Loan from HDFC Bank
Fischer Medical Ventures Ltd's subsidiary, Time Medical International Ventures (India) Private Limited, secured a ₹40 Crore secured loan from HDFC Bank Ltd. The loan agreement was executed on January 30, 2026, with shares pledged and FD collateral provided. The interest rate is 3 months Repo + 2.75% p.a.
The loan is for a subsidiary and its amount is not substantial enough to significantly impact the overall financials of Fischer Medical Ventures Limited.
The announcement details a standard loan agreement for a subsidiary, which is a routine business activity and does not inherently suggest positive or negative performance.
Fischer Medical Ventures Limited has announced that its material subsidiary, Time Medical International Ventures (India) Private Limited, has entered into a loan agreement with HDFC Bank Ltd. The Board of Directors of the holding company, Fischer Medical Ventures Ltd, approved this agreement during their meeting on January 30, 2026.
The loan agreement is for an amount of ₹40 Crores. The purpose of the agreement is for a loan, and it is a secured loan. The interest rate is set at 3 months Repo + 2.75% per annum. The loan agreement was executed on January 30, 2026. As security for the loan, shares have been pledged and Fixed Deposit collateral has been provided. The amount of loan outstanding as on the date of disclosure is Nil.
Time Medical International Ventures (India) Private Limited is the borrower, and HDFC Bank Ltd is the lender. The parties involved are not related to the promoter/promoter group/group companies of Fischer Medical Ventures Ltd. The transaction does not fall within related party transactions, or if it does, it is conducted at an arm's length basis. As of the disclosure date, there has been no termination, amendment, or alteration to the loan agreement.
What to do with a filing like this
Fischer Medical Ventures Limited filed this with the NSE as a statutory disclosure, categorised under debt fundraising. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fischer Medical Ventures Limited. Read the original for the full detail.